Abstract

Two infants with supraventricular tachycardia were given intravenous verapamil and subsequently suffered life threatening bradycardia and hypotension. As there were no predisposing factors, direct drug action is implicated and other reports of the adverse effects of verapamil are noted. Supraventricular tachycardia in neonates and young infants may be safely treated with digoxin and cardioversion, and intravenous verapamil should be avoided.